These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216 [TBL] [Abstract][Full Text] [Related]
29. Novel approaches and mechanisms of immunotherapy for glioblastoma. Hegde M; Bielamowicz KJ; Ahmed N Discov Med; 2014 Mar; 17(93):145-54. PubMed ID: 24641957 [TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in human glioblastoma. Szabo AT; Carpentier AF Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075 [TBL] [Abstract][Full Text] [Related]
32. Cell- and peptide-based immunotherapeutic approaches for glioma. Yamanaka R Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264 [TBL] [Abstract][Full Text] [Related]
33. Therapeutics and Research Related to Glioblastoma: Advancements and Future Targets. Chavda V; Patel V; Yadav D; Shah J; Patel S; Jin JO Curr Drug Metab; 2020; 21(3):186-198. PubMed ID: 32268863 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883 [TBL] [Abstract][Full Text] [Related]
35. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma. Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187 [TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in glioblastoma: emerging options in precision medicine. Hodges TR; Ferguson SD; Heimberger AB CNS Oncol; 2016 Jul; 5(3):175-86. PubMed ID: 27225028 [TBL] [Abstract][Full Text] [Related]
37. Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Johanns TM; Ward JP; Miller CA; Wilson C; Kobayashi DK; Bender D; Fu Y; Alexandrov A; Mardis ER; Artyomov MN; Schreiber RD; Dunn GP Cancer Immunol Res; 2016 Dec; 4(12):1007-1015. PubMed ID: 27799140 [TBL] [Abstract][Full Text] [Related]
38. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS Front Immunol; 2019; 10():2683. PubMed ID: 31798595 [TBL] [Abstract][Full Text] [Related]
39. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419 [TBL] [Abstract][Full Text] [Related]
40. Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Higgins RJ; McKisic M; Dickinson PJ; Jimenez DF; Dow SW; Tripp LD; LeCouteur RA Cancer Immunol Immunother; 2004 Apr; 53(4):338-44. PubMed ID: 14618278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]